Evidence map›Paper›PMID 38177231›Full record

ArticleNPJ vaccines2024

Antigen self-anchoring onto bacteriophage T5 capsid-like particles for vaccine design.

Emeline Vernhes, Linda Larbi Chérif, Nicolas Ducrot, Clément Vanbergue, Malika Ouldali, Lena Zig, N'diaye Sidibe, Sylviane Hoos, Luis Ramirez-Chamorro, Madalena Renouard and 5 more

Open access · goldAbstract read
In one paragraph

Article in NPJ vaccines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Engineering Microbial Particles for Next-Generation Biomedical Platforms.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

Emeline Vernhes *Université Paris-Saclay, CEA, CNRS, Institute for Integrative Biology of the Cell (I2BC), 91198, Gif-sur-Yvette, France.ORCID http://orcid.org/0000-0002-6662-5324
Linda Larbi Chérif *Université Paris-Saclay, Gustave Roussy, CNRS, Metabolic and systemic aspects of oncogenesis for new therapeutic approaches (METSY), 94805, Villejuif, France.
Nicolas DucrotUniversité Paris-Saclay, CEA, CNRS, Institute for Integrative Biology of the Cell (I2BC), 91198, Gif-sur-Yvette, France.ORCID http://orcid.org/0009-0007-6150-7832
Clément VanbergueUniversité Paris-Saclay, Gustave Roussy, CNRS, Metabolic and systemic aspects of oncogenesis for new therapeutic approaches (METSY), 94805, Villejuif, France.
Malika OuldaliUniversité Paris-Saclay, CEA, CNRS, Institute for Integrative Biology of the Cell (I2BC), 91198, Gif-sur-Yvette, France.
Lena ZigUniversité Paris-Saclay, Gustave Roussy, CNRS, Metabolic and systemic aspects of oncogenesis for new therapeutic approaches (METSY), 94805, Villejuif, France.
N'diaye SidibeUniversité Paris-Saclay, Gustave Roussy, CNRS, Metabolic and systemic aspects of oncogenesis for new therapeutic approaches (METSY), 94805, Villejuif, France.
Sylviane HoosInstitut Pasteur, Biophysique Moléculaire, CNRS UMR 3528, Paris, France.ORCID http://orcid.org/0000-0002-4029-562X
Luis Ramirez-ChamorroUniversité Paris-Saclay, CEA, CNRS, Institute for Integrative Biology of the Cell (I2BC), 91198, Gif-sur-Yvette, France.
Madalena RenouardUniversité Paris-Saclay, CEA, CNRS, Institute for Integrative Biology of the Cell (I2BC), 91198, Gif-sur-Yvette, France.
Ombeline RossierUniversité Paris-Saclay, CEA, CNRS, Institute for Integrative Biology of the Cell (I2BC), 91198, Gif-sur-Yvette, France.ORCID http://orcid.org/0000-0003-4987-1811
Patrick EnglandInstitut Pasteur, Biophysique Moléculaire, CNRS UMR 3528, Paris, France.ORCID http://orcid.org/0000-0001-6410-5918
Guy SchoehnUniv. Grenoble Alpes, CNRS, CEA, IBS, F-38000, Grenoble, France.ORCID http://orcid.org/0000-0002-1459-3201
Pascale BoulangerUniversité Paris-Saclay, CEA, CNRS, Institute for Integrative Biology of the Cell (I2BC), 91198, Gif-sur-Yvette, France. pascale.boulanger@i2bc.paris-saclay.fr.ORCID http://orcid.org/0000-0003-4912-5392
Karim BenihoudUniversité Paris-Saclay, Gustave Roussy, CNRS, Metabolic and systemic aspects of oncogenesis for new therapeutic approaches (METSY), 94805, Villejuif, France. karim.benihoud@gustaveroussy.fr.
Centre National de la Recherche Scientifique · FR

Funding

Ministère de l'Enseignement Supérieur, de la Recherche, de la Science et de la Technologie (MESRST) ED 582
6 · The paper itself

Abstract

The promises of vaccines based on virus-like particles stimulate demand for universal non-infectious virus-like platforms that can be efficiently grafted with large antigens. Here, we harnessed the modularity and extreme affinity of the decoration protein pb10 for the capsid of bacteriophage T5. SPR experiments demonstrated that pb10 fused to mCherry or to the model antigen ovalbumin (Ova) retained picomolar affinity for DNA-free T5 capsid-like particles (T5-CLPs), while cryo-EM studies attested to the full occupancy of the 120 capsid binding sites. Mice immunization with CLP-bound pb10-Ova chimeras elicited strong long-lasting anti-Ova humoral responses involving a large panel of isotypes, as well as CD8

Identifiers

PMID38177231
PMCPMC10766600
OpenAlexW4390590878

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.